NEW YORK (GenomeWeb) – Genomic Health reported after the close of the market Tuesday that its first quarter revenues rose 4 percent year over year, falling short of the consensus Wall Street estimate.

The company's total revenue for the three months ended March 31 was $84.0 million, compared with $80.9 million in the first quarter of 2016, mainly supported by growing prostate cancer and international test sales. Analysts had predicted revenues of $86.2 million on average.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.